Pralsetinib

For research use only. Not for therapeutic Use.

  • CAT Number: I020039
  • CAS Number: 2097132-94-8
  • Molecular Formula: C₂₇H₃₂FN₉O₂
  • Molecular Weight: 533.60
  • Purity: 98%
Inquiry Now

Pralsetinib(Cat No.:I020039)is a targeted RET inhibitor used to treat cancers driven by RET gene fusions or mutations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer, and other solid tumors. By selectively inhibiting RET kinase, Pralsetinib blocks the abnormal signaling pathways that promote cancer cell growth and proliferation. Its high specificity reduces off-target effects and improves safety. Pralsetinib has demonstrated significant clinical efficacy in patients with RET-altered cancers, especially those resistant to other treatments, providing a potent and personalized therapy option for managing advanced RET-driven tumors.


Catalog Number I020039
CAS Number 2097132-94-8
Molecular Formula C₂₇H₃₂FN₉O₂
Purity 98%
Target Protein

P07949

Appearance Solid
Storage Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
IC50 IC50: 0.4 nM (Wild type RET), 0.3 nM (RET V804L), 0.4 nM (RET V804M), 0.4 nM (RET M918T), 0.4 nM (CCDC6-RET)
IUPAC Name N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
InChI InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
InChIKey GBLBJPZSROAGMF-SIYOEGHHSA-N
SMILES CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
Reference

[1]. Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.

Request a Quote